BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Envlo (Enavogliflozin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Envlo (Enavogliflozin)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06580717-312@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Envlo (Enavogliflozin): Phase 4 readout est. (NCT06580717)
DESCRIPTION:Envlo (Enavogliflozin)\, phase 4.\nStudy: ENavogliflozin DElive
 ring Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hy
 pertrophic CardioMyopathy\nEstimated primary completion: 30 November 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/enavogliflozin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06580717
URL:https://assetmemo.bio/drug/enavogliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06399835-312@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envlo (Enavogliflozin): Phase 4 readout est. (NCT06399835)
DESCRIPTION:Envlo (Enavogliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: Ena
 vogliflozin vs. Pioglitazone on Glucose and Atherosclerosis\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/enavogliflozin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06399835
URL:https://assetmemo.bio/drug/enavogliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07240844-312@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:Envlo (Enavogliflozin): Phase 4 readout est. (NCT07240844)
DESCRIPTION:Envlo (Enavogliflozin)\, phase 4.\nStudy: Enavogliflozin for th
 e Management of Patients With Amyloid CardiomyopaThy\nEstimated primary co
 mpletion: 29 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/enavogliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07240844
URL:https://assetmemo.bio/drug/enavogliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06528262-312@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Envlo (Enavogliflozin): Phase 4 readout est. (NCT06528262)
DESCRIPTION:Envlo (Enavogliflozin)\, phase 4.\nStudy: Effect of Enavogliflo
 zin on Recurrence of Atrial Fibrillation After Catheter Ablation\nEstimate
 d primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/enavogliflozin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06528262
URL:https://assetmemo.bio/drug/enavogliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06027307-312@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Envlo (Enavogliflozin): Phase 3 readout est. (NCT06027307)
DESCRIPTION:Envlo (Enavogliflozin)\, phase 3.\nStudy: Enavogliflozin Outcom
 e Trial in Functional Tricuspid Regurgitation\nEstimated primary completio
 n: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enavogl
 iflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06027307
URL:https://assetmemo.bio/drug/enavogliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619833-312@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Envlo (Enavogliflozin): Phase 3 readout est. (NCT07619833)
DESCRIPTION:Envlo (Enavogliflozin)\, phase 3\, Type 2 Diabetes.\nStudy: To 
 Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16
 001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monothera
 py in Patients With Type 2 Diabetes Mellitus\nEstimated primary completion
 : November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enav
 ogliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07619833
URL:https://assetmemo.bio/drug/enavogliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05672836-312@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Envlo (Enavogliflozin): Phase 4 readout est. (NCT05672836)
DESCRIPTION:Envlo (Enavogliflozin)\, phase 4.\nStudy: ENAVOgliflozin Outcom
 e Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic
  Valve Replacement\nEstimated primary completion: December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/enavogliflozin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05672836
URL:https://assetmemo.bio/drug/enavogliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06642623-312@assetmemo.bio
DTSTAMP:20261121T005012Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Envlo (Enavogliflozin): Phase 4 readout est. (NCT06642623)
DESCRIPTION:Envlo (Enavogliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: A P
 rospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Typ
 e 2 Diabetes Mellitus Patients\nEstimated primary completion: 30 September
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/enavogliflozin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066
 42623
URL:https://assetmemo.bio/drug/enavogliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
